Showing papers by "Luisa Imberti published in 2003"
TL;DR: At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation.
Abstract: Among 165 HIV-infected patients, prevalence of SEN virus (SENV) infection was 51.5%, with subtype A predominance and unique SENV variant (67%), but also SENV superinfections with multiple variants were frequent. High prevalence, superinfection and broad SENV subtype diversification have been demonstrated, all linked to intravenous drug use (IVDU) as a risk factor for HIV acquisition. At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation.
7 citations
Journal Article•
TL;DR: SENV has no apparent clinical relevance during highly active antiretroviral therapy, according to persistent fluctuations in SENV-A positivity, suggesting that concomitant infections could influence the outcome of antiviral treatment.
Abstract: Since it has been demonstrated that concomitant infections could influence the outcome of antiviral treatment, we investigated whether the presence of SENV infection may interfere with highly active antiretroviral therapy (HAART) in HIV+ coinfected patients. In spite of persistent fluctuations in SENV-A positivity we could not find any correlation between SENV-DNA and the immunological and virologic parameters found in the patients, suggesting SENV has no apparent clinical relevance during highly active antiretroviral therapy.
1 citations